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INTRODUCTION 
Diabetes is an important risk factor for the development of 
coronary artery disease (CAD). CAD accounts for about 70-80% of death 
in diabetic patients1,2. Patients with diabetes develop CAD at an 
accelerated rate and have a higher incidence of heart failure, myocardial 
infarction, and cardiac death compared to non-diabetics3. Moreover, 
compared with non-diabetic patients, diabetic patients have lower ejection 
fraction and more frequent silent myocardial infarction4-9.  
Diabetic patients have a more extensive coronary atherosclerosis 
and their epicardial vessels are less amenable to interventional treatment 
compared with the non-diabetic population10-12. These findings can easily 
explain the poor outcome of these patients. CAD in diabetic patients is 
detected at an advanced stage, whereas the disease in its premature, 
asymptomatic stages remains undetected because the typical anginal 
symptoms are often masked13. As a consequence, multivessel 
atherosclerosis is often  present before anginal symptoms occur and 
before treatment can be instituted14-15. Undoubtedly a delayed recognition 
of CAD worsens the prognosis for survival. So an effective and 
aggressive strategy for early detection of subclinical CAD could lead to a 
more effective prevention and can reduce morbidity and mortality in 
these patients. 
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One of the diagnostic tools for the diagnosis and risk stratification 
of coronary heart disease is exercise stress testing, whose diagnostic and 
prognostic value has been studied extensively. Electrocardiograph (ECG) 
exercise stress testing is a reliable and widely used method for evaluating 
patients who are at increased risk of developing cardiovascular disease. 
The predictive value of the exercise stress test is greatest when test results 
are combined with family history, current cardiac symptoms, and 
underlying risk factors. Combining clinical information with test data 
yields a 94% sensitivity and 92% specifcity.16 
  Many studies have demonstrated that a significant percentage of 
patients with diabetes who have no symptoms of CAD have abnormal 
stress tests, either by stress ECG, stress echocardiogram, or stress nuclear 
perfusion imaging. It has also been demonstrated that patients with silent 
myocardial ischemia have a poorer prognosis than those with normal 
stress tests, and their risk is further increased if cardiac autonomic 
neuropathy coexists.17 
So as the number of individuals who develop diabetes increases in 
developing countries like India, more patients will need to undergo 
detailed cardiovascular assessment. Although diagnosing and treating 
patients with diabetes and associated CAD is essential, the proper 
screening method for detecting the disease and its evaluation remains a 
constant challenge. 
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PAD is a common problem in diabetic patients and it has the 
ability to predict future cardiac events in these individuals. The role of the 
ankle/brachial index (ABI) in the detection of asymptomatic PAD, 
especially in diabetic individuals, is well established18,19.   
The American Diabetes Association (ADA) quotes the normal 
range of ABI as being 0.91–1.320. An ABI of ≤0.90 is 95% sensitive and 
99% specific for angiographically documented PAD. The specificity of 
low ABI for coronary heart disease, stroke, and cardiovascular mortality 
was 92.7%, 92.2%, and 87.9%, respectively. ABI >1.40 predicts 
mortality with similar strength as ABI ≤0.90.It’s not just about the legs, 
in asymptomatic individuals, the ABI should be thought of as a biomarker 
of cardiovascular disease risk21. 
So it’s high time to assess the ABI as a predictor of silent 
myocardial ischemia in asymptomatic type 2 DM patients hailing from 
India so that we can identify those who are at increased risk of future 
cardiovascular events earlier. By instituting the appropriate therapy we 
can decrease the mortality and morbidity in these patients. 
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AIMS AND OBJECTIVES 
AIM 
 To asses ankle brachial index (ABI) as a predictor of silent 
myocardial ischemia in asymptomatic type 2 DM patients. 
OBJECTIVES 
PRIMARY 
1. To measure ankle brachial index (ABI) using hand held Doppler in 
asymptomatic type 2 DM patients. 
2. To assess the presence of silent myocardial ischemia (SMI) in 
asymptomatic type 2 DM patients. 
3. To evaluate the relationship between ankle brachial index (ABI) 
and silent myocardial ischemia (SMI) in asymptomatic type 2 DM 
patients. 
SECONDARY 
 To assess the risk factors associated with development of silent 
myocardial ischemia in asymptomatic type 2 DM patients. 
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REVIEW OF LITERATURE 
Cardiovascular disease is the leading cause of mortality in people 
with diabetes. Diabetic individuals have a 2 to 4 fold increased risk for 
having cardiovascular events compared to patients without diabetes22. 
People with diabetes have a two to three fold greater morbidity and 
mortality following a myocardial infarction23. Although diabetic patients 
have a higher prevalence of traditional CAD risk factors such as 
hypertension, dyslipidemia and obesity when compared with people 
without diabetes, these risk factors account for less than half the excess 
mortality associated with diabetes. Thus, the diagnosis of diabetes is a 
major independent risk factor for the development of CAD and for 
adverse outcomes following a cardiovascular event. 
Many therapies have been shown to be beneficial for reducing the 
cardiovascular events in people with diabetes such as treatment of 
hypertension and dyslipidemia and the use of aspirin, ACE inhibitors and 
ß blockers. However, early identification of patients with CAD is very 
essential for these therapies to be maximally effective in diabetic patients. 
Recognition of a previously undiagnosed myocardial infarction or 
knowledge of the presence of CAD will have an impact on the type and 
aggressiveness of therapy to be given. In patient with diabetes who had 
no symptoms of CAD, clinicians must decide when to initiate testing for 
CAD, and equally important, what testing algorithm is optimal.  
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CAD IN DIABETES 
Most of the Type 2 DM patients frequently have many of the 
traditional CAD risk factors and usually present with CAD in the 5th or 
6th decade of life or later, often after a relatively short period from 
diagnosis of diabetes, or even at diagnosis unlike type 1 DM patients. 
Not infrequently, diabetes is first identified when the patient with 
CAD presents with angina, MI, or heart failure. The premature 
occurrence of CAD in diabetic patients, the more extensive coronary 
artery disease at the time of diagnosis, and the higher morbidity and 
mortality following MI are due to the more diffuse and distal involvement 
of coronary arteries in these patients24. 
CAD in diabetes is associated with generalized endothelial 
dysfunction and abnormalities of small vessels as well. Diabetic patients, 
more frequently have multiple coronary vessels involved by the time 
coronary artery disease is diagnosed or at the time of myocardial 
infarction. Diabetic patients are more prone for developing congestive 
heart failure because of the more diffuse coronary atherosclerotic process, 
particularly in the post myocardial infarction setting25. However, 
impaired ventricular function in diabetes is not only limited to the post-
MI setting because impaired diastolic function has also been 
demonstrated in diabetic patients even in the absence of significant 
atherosclerotic CAD26. 
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Acute coronary syndromes such as acute MI, unstable angina, and 
perhaps sudden death, commonly have luminal thrombus formation. Over 
time, increased thrombotic activity may accelerate the atherosclerotic 
process. The coagulation abnormalities associated with diabetes such as 
increased platelet aggregation and increased levels of fibrinogen and 
plasminogen activator inhibitor (PAI-1) may accelerate the development 
of coronary artery thrombosis. Increased platelet aggregation is related to 
the hyperglycemia of diabetes and insulin resistance. 
Hypertriglyceridemia and hyperinsulinemia which are frequently seen in 
diabetes may be related to the elevated levels of PAI-127. 
The autonomic innervations of the heart can be affected in people 
with diabetes, which leads to a characteristic elevation in resting heart 
rate and decreased beat to beat variation. As autonomic dysfunction 
progresses, the heart rate response to posture or Valsalva manoeuvre and 
the circadian changes in blood pressure are both diminished. 
Symptomatic autonomic neuropathy increases the risk of sudden death in 
people with diabetes. Cardiovascular autonomic neuropathy occurs in 
≈17% of patients with type 1 diabetes and ≈22% of those with type 2 
DM28. Silent myocardial ischemia in diabetic patients is also contributed 
by cardiac autonomic neuropathy and this complicates the detection of 
CAD29. As a consequence, diabetic patients may be asymptomatic or 
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present with atypical symptoms such as easy fatigability, exertional 
dyspnoea, or indigestion. 
BENEFITS OF EARLY DIAGNOSIS 
The potential benefits of diagnosing asymptomatic CAD in patients 
with diabetes include  
1) The early implementation of preventive programs aimed at 
reducing the risk of future coronary morbidity and mortality 
2) The early initiation of anti-ischemic medications, and  
3) The early identification of the patient for whom revascularization is 
appropriate. 
Evidence from subgroup analysis of many secondary prevention trials 
enrolling diabetic patients with known CAD indicates that aggressive 
treatment can effectively reduce cardiovascular morbidity and 
mortality30,31. Although these results support the risk factor intervention 
in patients with diabetes and known CAD, similar data are lacking for a 
population of patients with asymptomatic coronary artery disease. 
Nevertheless, the increased morbidity and mortality from CAD in patients 
with diabetes provides a rationale for diagnostic evaluation in 
asymptomatic diabetic patients and aggressive "secondary" intervention 
when CAD is identified. 
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THE DESIGN OF PREVENTION PROGRAMS 
The most compelling rationale at the present time for prompt 
diagnosis of coronary artery disease in patients with diabetes is the 
striking benefits observed in the lipid lowering trials. In the Scandinavian 
Simvastatin Survival Study (4S), cholesterol lowering was associated 
with a 42% reduction in cardiovascular mortality and a 30% reduction in 
total mortality in an overall group of 2,200 men and women with 
coronary disease, compared with placebo30. About 5% of the subjects had 
diabetes, and simvastatin treatment in that group was associated with a 
55% reduction in major coronary events. In another study, the Cholesterol 
and Recurrent Events Trial (CARE)31, where 14% of the participants had 
diabetes, a 25% reduction in CAD events was seen with pravastatin 
therapy in both the diabetic and non-diabetic patients. Thus, early 
diagnosis of asymptomatic CAD disease should encourage aggressive 
lipid lowering therapy. The National Cholesterol Education Program 
(NCEP) guidelines32 and the recently published 2010 ADA 
recommendations for treating dyslipidemia33 set different goals of therapy 
according to the absence or presence of coronary artery disease. This 
distinction suggests that the diagnosis of presymptomatic CAD should 
influence therapeutic decisions. 
In patients with diabetes control of hypertension is so essential to 
reduce the onset and progression of diabetic nephropathy. The Joint 
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National Committee (JNC) 7 report recommends that patients with 
diabetes should be treated to reduce the blood pressure to a goal of < 
130/8034. The presence of coronary artery disease or abnormal left 
ventricular function decides the choice of the selection of 
antihypertensive agent. 
There are no well controlled studies to show that improved glucose 
control will reduce cardiovascular disease in patients with diabetes. 
However, in the Diabetes Control and Complications Trial (DCCT)35, the 
intensive treatment group had a trend toward fewer cardiovascular events, 
although the number of actual events in this relatively young group of 
individuals was very low, and the effect of treatment did not reach 
statistical significance. In the Diabetes Mellitus Insulin Glucose Infusion 
in Acute Myocardial Infarction (DIGAMI) Study36, hospital use of insulin 
glucose infusion, followed by 3 months of intensive insulin therapy in 
patients with acute MI, was associated with a 29% reduction in 
cardiovascular mortality after 1 year. Similarly in UKPDS Study the 
author found that the only macrovascular end point that demonstrated a 
trend in risk reduction in the main analysis was myocardial infarction 
(MI) (16% risk reduction), but did not quite reach statistical 
significance37.From these studies we can understand that aggressive 
glycemic control will be another approach to the prevention of cardiac 
events but more studies will be needed to assess its real significance. 
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The efficacy of aspirin therapy in reducing CAD has been studied 
extensively. The diabetic subjects included in the Meta analysis of 145 
prospective studies of aspirin use conducted by the Anti-Platelet 
Trialists38 had reductions in MI, stroke, transient ischemic episodes, or 
development of signs and symptoms of coronary disease similar to non-
diabetic subjects. In the Early Treatment Diabetic Retinopathy Study 
(ETDRS)39, diabetic patients without pre existing coronary artery disease 
who received aspirin had a 15% reduction in the incidence of first MI 
over a 7-year period. In that study, diabetic patients with pre existing 
CAD also benefited. In a sub-group analysis of the Physicians Health 
Study 40, diabetic physicians receiving aspirin for primary prevention had 
a reduced relative risk of MI. These data have led the ADA to 
recommend the consideration of aspirin therapy for primary prevention in 
those with diabetes at increased cardiovascular risk that includes men >50 
years of age or women >60 years of age with at least one additional major 
risk factor and the use of aspirin therapy as a secondary prevention 
strategy in men and women with evidence of large vessel disease41.  
ACE inhibitors are recommended as the first line treatment of 
hypertension in diabetes and in diabetic patients with proteinuria42. 
However, the demonstration of coronary artery disease, and identification 
of left ventricular dysfunction, would also be a strong indicator for ACE 
inhibitor treatment in the normotensive, non proteinuric patient.  
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INITIATION OF ANTI-ISCHEMIC THERAPY 
In patients with diabetes who have had an MI, ß blocker treatment 
is very important to reduce the mortality. So, the diagnosis of a 
previously unrecognized MI in these patients is critical in the 
management. In the Bezafibrate Infarction Prevention Study43, patients 
treated with ß-blockers had an approximately 50% reduction in mortality, 
compared with those patients not receiving that treatment. ß Blocker 
therapy was also effective in the DIGAMI Study36. Also, the use of 
cardioselective ß blockers is particularly beneficial in diabetic patients 
with reduced heart rate variability. 
REFERRAL FOR REVASCULARIZATION 
Testing for asymptomatic coronary disease may help identify 
patients with severe coronary obstruction in whom revascularization 
should be considered, although the benefit of percutaneous transluminal 
coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) in 
people with asymptomatic CAD and diabetes is not clear. The Bypass 
Angioplasty Revascularization Investigation (BARI) trial44 indicated 
excellent 5-year survival in symptomatic diabetic patients with advanced 
multi-vessel coronary disease treated with CABG. In the same study, 
selected patients who received an internal mammary artery graft, cardiac 
mortality was 2.9% at 5 years. On the other hand, the BARI trial raised 
serious concern for the use of PTCA in multi-vessel disease, since 
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diabetic patients randomized to PTCA had a greatly increased 5-year 
mortality (35% overall and 20% cardiac) compared with patients 
randomized to CABG with or without an internal mammary artery graft 
(19% overall and 6% cardiac). Subgroup analyses of the Emory 
Angioplasty versus Surgery Trial (EAST)45 and the Coronary 
Angioplasty versus Bypass Revascularization (CABRI)46 trials showed 
that CABG tended to be associated with better long-term survival over 
balloon only PCI for 3-vessel disease 
Although nonrandomized patients in the BARI registry and other 
patients in observational studies with multi-vessel disease have shown a 
higher survival rate when treated with PTCA, there still remains concern 
for the use of multi-vessel PTCA to improve the prognosis in 
asymptomatic patients with diabetes. The higher restenosis rate 
associated with PTCA in diabetic patients (up to 63%)47 also limits the 
use of routine balloon angioplasty for asymptomatic patients with single-
vessel disease.  
ROLE OF CARDIAC TESTING 
People with diabetes may present for evaluation with an established 
CAD history or for having a prior cardiac event, in which case they 
warrant testing for risk stratification. However, the challenge faced by the 
physician caring for a patient with diabetes is to accurately identify 
patients without a prior history of a cardiovascular event and patients not 
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manifesting the symptoms strongly suggesting CAD, in whom additional 
testing is indicated.  
There are no evidence based guidelines for screening asymptomatic 
diabetic patients for coronary artery disease (CAD). One well studied 
screening tool is exercise treadmill testing. Many diabetic patients with 
no symptoms of CAD have abnormal stress tests. For asymptomatic 
patients, identification of cardiovascular risk factors and risk stratification 
may help physicians justify the performance of treadmill evaluation. 
Patients considering moderate or vigorous exercise and those at highest 
risk can undergo exercise stress testing with referral for further evaluation 
as indicated. For patients with decreased exercise capacity, inability to 
reach target heart rates, or absence of chest pain during exercise, stress 
nuclear imaging may be more valuable than exercise electrocardiograph 
testing. In general, the test chosen will depend on the purpose of the test. 
The American Heart Association Prevention VI Conference48 
emphasized that there are no outcome data to support stress testing in 
asymptomatic diabetic patients. 
INDICATIONS FOR STRESS TESTING IN DIABETIC PATIENTS 
The ADA49 advocates for stress testing in diabetic patients with 
1. Typical or atypical cardiac symptoms 
2. Resting electrocardiograph suggestive of ischemia or infarction 
3. Peripheral or carotid occlusive arterial disease 
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4. Sedentary lifestyle, age >35 years, and planning to begin a 
vigorous exercise program 
5. Two or more of the following risk factors in addition to diabetes 
• Total cholesterol ≥240 mg/dl, LDL cholesterol ≥160 mg/dl, 
or HDL cholesterol ≤35 mg/dl 
• Blood pressure ≥140/90 mmHg 
• Smoking 
• Family history of premature CAD 
• Positive micro/macro albuminuria test. 
Ambulatory monitoring of ST segment changes 
Chiariello et al50 compared the incidence of ambulatory ischemia 
during 24-hour AECG monitoring among 51 patients with diabetes (74% 
of whom had evidence of coronary disease), 70 nondiabetic patients with 
coronary disease, and 40 nondiabetic patients without overt coronary 
disease. They reported that 36% of the diabetic patients had at least one 
episode of asymptomatic ischemia, significantly higher than the 17% of 
patients in the nondiabetic group with coronary disease. Additionally, 
73% of the total episodes of ST-segment deviation in the diabetic group 
were asymptomatic, significantly higher than the 60% of episodes in the 
nondiabetic group. 
In the Asymptomatic Cardiac Ischemia Pilot (ACIP)51, ≈90% of 
patients had only asymptomatic ST-segment depression during the 
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qualifying 48-hour AECG recording. There was no difference in the 
prevalence of asymptomatic ST-segment depression in the diabetic and 
nondiabetic ACIP groups 
In general, the utility of ambulatory monitoring of 
electrocardiographic ST-segment changes to detect coronary disease in 
asymptomatic populations has been disappointing and not cost effective.  
Coronary artery calcification: 
The coronary calcium score is an excellent marker for the overall 
coronary atherosclerotic burden and identifies asymptomatic individuals 
at higher risk for inducible ischemia. If in the judgment of the clinician an 
asymptomatic patient is a candidate for CAD testing, it is reasonable to 
apply cardiac CT for detection of coronary artery calcification, using 
either electron beam or multislice technology, as the first step. The 
calcium score may also identify those at risk of subsequent coronary 
events but should be used with full knowledge of the patient’s complete 
cardiovascular risk profile. 
The American Heart Association scientific statement52 states that 
coronary calcium testing is not valuable in individuals at low 
Framingham risk but may be useful as a screening tool in those at 
intermediate risk, which would include patients with diabetes. However, 
there was only limited support for coronary calcium testing of patients at 
intermediate risk, with a class IIb recommendation (level of evidence B). 
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Moreover, the American College of Cardiology appropriateness criteria 
for cardiac CT53 indicates that the usefulness of screening asymptomatic 
intermediate risk populations with this technology is currently 
unknown54. Anand et al.55 studied asymptomatic patients with diabetes 
and confirmed the higher incidence of inducible ischemia in patients with 
higher calcium scores. If coronary calcium testing is performed, it 
appears reasonable to proceed with further testing in diabetic patients 
with calcium scores >400, considering factors such as age and renal 
function. The higher cost of the investigation precludes its availability to 
the general population. 
Exercise electrocardiography 
Exercise ECG testing remains a well established, inexpensive test 
available to assist clinicians in the diagnosis and prognosis of CAD in 
diabetic patients. It appears to have similar diagnostic sensitivity (≈50%) 
and specificity (≈80%) for diabetic patients presenting with angina as for 
non-diabetic patients56. It can identify a subgroup of asymptomatic 
diabetic patients who have significant CAD as defined by angiography, 
and in lower risk diabetic cohorts, it may offer short term prognostic 
reassurance to those asymptomatic patients with negative tests. However, 
considerable prognostic power of the exercise ECG test lies beyond the 
ST-segment response and the presence of angina during exercise.  
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Parameters including exercise capacity and HRR (Heart Rate 
Recovery) offer significant information, particularly in diabetic patients, 
who may not experience angina during exercise and who may have 
increased autonomic dysfunction. P Michael Ho et al57 showed that 
impaired chronotropic response to exercise stress testing in patients with 
diabetes predicts future cardiovascular events. Further studies are needed 
to assess the value of these non ST segment variables among patients 
with DM. 
Stress perfusion imaging 
This investigation requires the effort on the patient side to walk. In 
elderly patients who have associated osteoarthritis, this may be a difficult 
investigation to perform. 
Stress nuclear testing has a sensitivity of 88% and specificity of 
74% for the detection of angiographic CAD in the general clinical 
population and has been found to have similar diagnostic value among 
diabetic cohorts58. Stress nuclear testing appears to be useful in risk 
stratification among higher risk asymptomatic diabetic patients. 
 In the largest series reported, Rajagopalan and colleagues59 
assessed the prognostic implications of stress nuclear testing in their 
cohort of 1427 asymptomatic diabetic patients. When patients were 
stratified by their stress nuclear test results into low, medium, and high 
risk groups, the authors found a significant difference among annual 
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mortality rates (3.6%, 5.0%, and 5.9% respectively) . De Lorenzo et al60 
reported that among 180 asymptomatic diabetic patients who underwent 
exercise or dipyridamole nuclear stress testing, 26% had abnormal 
SPECT imaging. Death or MI occurred in 3% of those with no perfusion 
defects, 10% of those with perfusion defect in a single territory, and 31% 
of those with perfusion defects that involved more than 1 territory. 
In summary, perfusion imaging is useful in patients with diabetes 
since the technique provides quantifiable data and identifies low and high 
risk patients for future adverse cardiovascular events. However, the 
expertise and technical requirements required for performing nuclear 
testing is not widely available in India and is beyond the reach of the 
common man.  
Stress echocardiography 
Stress echocardiography has a mean sensitivity of 86% and a 
specificity of 81% in the general population61.  Hennessy et al62 evaluated 
52 patients with DM referred for cardiac assessment using dobutamine 
stress echocardiography (DSE). Sensitivity, specificity, and positive and 
negative predictive values of DSE for CAD detection were 82%, 54%, 
84%, and 50%, respectively. 
Penfornis et al63 compared the efficacy of DSE to exercise ECG 
testing and SPECT (Single Photon Emission Computed Tomography) 
nuclear perfusion imaging in 56 asymptomatic diabetic patients with 3 
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additional cardiovascular risk factors but normal resting ECGs. 
Participants underwent all forms of non-invasive stress testing, but 
coronary angiography was only performed if at least 1 test was abnormal 
(47%), which precluded the measurement of diagnostic sensitivity and 
specificity. Positive predictive value was 69% for DSE, 60% for exercise 
ECG and 75% for thallium SPECT.  
Stress echocardiographic imaging provides improved sensitivity 
and specificity compared with exercise ECG testing. Increasing data are 
available to support both its diagnostic accuracy and in particular, its 
prognostic ability to risk stratify diabetic patients for future cardiac events 
ANLKLE BRACHIAL INDEX 
There are several established procedures for estimating subclinical 
atherosclerotic changes in human arteries. Increased carotid intima media 
thickness (IMT) is associated with future cerebrovascular and 
cardiovascular events64,65. Pulse wave velocity is related to arterial wall 
stiffness, future hypertension and cardiovascular diseases66,67. Coronary 
artery calcium screening is the another method for evaluating the CVD 
risk in asymptomatic patients68-70. All these methods, however, require 
sophisticated equipment and a specialized user. Accordingly, they are not 
well suitable for the screening of early arterial changes in a routine office 
practice and there is a great need for a simple non invasive tool that could 
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be used in an office setting to screen for arterial stiffness or subclinical 
atherosclerosis such as ankle brachial index (ABI) 
The ankle blood pressure is usually measured in conjunction with 
the arm blood pressure and the ankle brachial pressure index (ABI) is 
calculated. Decreased ABI is strongly associated with cardiovascular 
diseases71-80. Also an elevated ABI value seems to be a significant risk 
factor of CVD81,82. The ankle brachial index (ABI) is widely accepted as 
a diagnostic test used to evaluate the presence of lower extremity 
peripheral artery disease (PAD) in patients with symptoms of intermittent 
claudication or rest ischemia83-85. However, the majority of patients with 
PAD are asymptomatic and therefore, measurement of the ABI only 
when prompted by symptoms will result in most cases of PAD going 
unrecognized86. 
The measurement of the ABI in patients without symptoms of PAD 
is controversial. In 2005, the United States Preventive Services Task 
Force assigned a “D” recommendation to screening for PAD, a grade 
indicating minimal benefit and possible harm87. This recommendation 
was based on evaluation of limb outcomes such as claudication, 
amputation, and impaired ambulation. However, most patients with PAD 
do not go on to have major adverse limb outcomes. They do, however, 
have an excessively high burden of cardiovascular morbidity and 
mortality. Diehmand et al88,89 make an important contribution to the 
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mounting evidence that screening for PAD in asymptomatic individuals 
should be considered in terms of cardiovascular and not limb outcomes.  
In the German Epidemiological Study on Ankle Brachial Index 
(getABI)90, a prospective observational cohort study on the prognosis of 
elderly (aged >65 years) individuals with a low ABI compared with those 
with a normal ABI, they reported that 21% of subjects screened had PAD 
and the presence of PAD was associated with a 2-fold adjusted risk of 
death or severe cardiovascular events. In persons with PAD, the risk of a 
severe coronary vascular event was 3-fold that of a peripheral vascular 
event. Their findings reinforce the concept that the measurement of the 
ABI as a part of primary care practice would identify a significant 
number of persons at heightened risk for cardiovascular morbidity and 
mortality and that limb events are infrequent relative to total 
cardiovascular events in patients with PAD. Thus, the greatest relevance 
of the ABI may not be for the limb but rather as a biomarker of 
cardiovascular risk. 
THE ABI AS A BIOMARKER OF CARDIOVASCULAR RISK: 
A National Institutes of  Health working  group defined a 
biomarker as “a characteristic that is objectively measured and evaluated 
as an indicator of normal biological processes, pathogenic processes, or 
pharmacological responses to a therapeutic intervention”91.The ABI 
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meets this definition as an objectively measured indicator of a pathogenic 
process. 
It measures a specific pathology (i.e., systemic atherosclerosis) 
because the cumulative prevalence of non-atherosclerotic causes of a low 
ABI (eg. giant cell arteritis) is very low. It adds to clinical assessment 
because the history and physical examination are often insufficient to 
correctly diagnose or rule out PAD92. The ABI is acceptable to the patient 
because it causes only mild discomfort and poses no risk such as radiation 
exposure. Most often, a single measure is sufficient to diagnose PAD85. It 
is applicable to men and women of all ages and has been tested in 
numerous ethnicities. The measurement is standardized, and it is both 
accurate and precise. The ABI has known reference limits; an ABI ≤0.90 
has been validated as both a sensitive and a specific marker of PAD. Its 
specificity is not only for the presence of PAD but also for adverse 
cardiovascular outcomes, making it unlikely to mislabel or harm 
asymptomatic individuals93. It has been tested in healthy individuals as 
well as in persons with varying severity of cardiovascular disease. The 
measurement takes only a few minutes, it does not require specialized 
equipment or a specialized technician, and has immediate turn around. A 
previous report from the getABI group demonstrated that the ABI 
determination is highly reproducible and reliable when done in a primary 
care setting by physicians and non-physicians with little training94. 
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There is a consistent series of prospective epidemiological studies 
indicating that an abnormal ABI predicts cardiovascular disease. A 
systematic review and meta-analysis including 7 population based studies 
with a total of 28,679 subjects found a consistent relationship between a 
low ABI and an adverse cardiovascular prognosis. The specificity of low 
ABI for coronary heart disease, stroke, and cardiovascular mortality was 
92.7%, 92.2%, and87.9%, respectively. The adjusted relative risk for 
cardiovascular mortality ranged from 2.0 to 6.393.  
A patient level meta analysis (ABI Collaboration) highlights that a 
low ABI predicts cardiovascular disease in those without a history of 
coronary heart disease95. In this analysis of 16 studies including 48,294 
individuals, a low ABI conferred an adjusted relative risk for 
cardiovascular mortality of 2.9 in men and 3.0 in women. Diehm et al 
found that PAD was associated with an adjusted relative risk for 
cardiovascular mortality of 2.1, consistent with the results of these meta-
analyses95. A final important aspect of the ABI as a cardiovascular 
disease biomarker is that it adds to the ability to predict risk over and 
above that already achievable through the use of established 
cardiovascular risk factors. The ABI Collaboration found that including 
the ABI in addition to the widely used Framingham Risk Score 
reclassified 19% of men and36% of women into a different category of 
risk95. 
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 Diehm et al88,89  did not test whether PAD reclassified patient risk, 
although they did demonstrate that the association of PAD with incident 
cardiovascular disease was independent of cardiovascular risk factors. In 
fact, the presence of PAD was the strongest predictor of death or severe 
vascular events in a fully adjusted multivariable model. 
PAD IN PEOPLE WITH DIABETES 
Peripheral arterial disease (PAD) is a frequent manifestation of 
atherosclerosis in the general population and is two to four times more 
prevalent in diabetic patients96. A continuous wave Doppler measured 
ankle brachial index (ABI) ≤0.90 is commonly used for diagnosing 
PAD83,86. Ankle brachial index (ABI) sensitivity is 79% and specificity is 
96% for detection of ≥50% reduction in vascular lumina97. Moreover, 
ABI has prognostic value for cardiovascular morbidity and mortality and 
for coronary artery disease in particular98. 
The ADA consensus panel states that PAD in people with diabetes 
is different from the vascular disease due to other risk factors in its 
biology, in its clinical presentation, and in its management. As far as the 
prevalence and impact are concerned, diabetes is the most powerful risk 
factor for PAD. Among those with diabetes, age, duration of diabetes, 
and the presence of neuropathy are particularly important as risk factors 
for the development of PAD99. 
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With diabetes, there is usually a unique involvement of the tibial 
vessels below the knee. Because of the pattern of involvement distally, 
the majority of patients lack classic symptoms, such as claudication. In 
addition, there is an almost invariable association with neuropathy with 
blunted pain perception. Patients are therefore likely to experience more 
subtle symptoms (fatigue or poor functioning) than with classic 
claudication. A more devastating consequence of neuropathy is that PAD 
patients with diabetes present late, having already developed limb 
threatening ischemia with tissue loss, gangrene, or rest pain. This 
unfortunate progression lends urgency to the task of uncovering PAD in 
asymptomatic individuals in order to prevent amputation. Beyond the 
threat to the limb, these patients face enormous cardiovascular and 
cerebrovascular risk.  
Over 5 years, 20% of PAD patients will sustain nonfatal 
myocardial infarction or stroke, and 30% will die, largely from 
cardiovascular disease100. For those with critical limb ischemia, the 
prognosis is worse: 30% will have amputations, and 20% will die within 
6 months86. The true prevalence of PAD in individuals with diabetes has 
been difficult to determine because of the lack of symptoms and 
insensitive means of diagnosis. Using the ABI, a study done by Elhadd et 
al found that the prevalence of PAD in individuals with diabetes > 40 
years of age was around 20%100,101.That figure is higher than would be 
27 
 
anticipated using only symptoms and absent pulses. In PAD patients > 50 
years of age, the diabetes prevalence was 29%, again higher than 
anticipated102.The unexpectedly very high prevalence of Peripheral 
Artery Disease in the population with diabetes in a sense makes PAD a 
new public health issue. 
It is important for clinicians to assess patients for PAD to identify 
those with high cardiovascular risk and those at risk for amputation. 
Because of the lack of symptoms in the premorbid period, it is important 
to screen those at risk. The ADA consensus statement recommends 
screening for PAD in anyone with diabetes over 50 years of age. Those 
with other risk factors (e.g., smoking, advanced age, hypertension, and 
hyperlipidemia) or a duration of diabetes > 10years should also be 
screened103. 
Measurement of ABI is more reliable and more specific than what 
can be learned from the history and physical exam. Medial arterial 
calcification can make arteries at the ankle poorly compressible, giving a 
false elevation of the ABI, typically > 1.3. Such false negatives are not 
common enough, however, to detract from the value of the ABI as a 
screening tool. If one suspects non-compressible vessels, then more 
detailed evaluation with toe pressure or pulse volume recordings would 
be indicated.  
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Finally, it should be noted that ABI screening for PAD in patients 
with diabetes is enormously productive. As noted above, routine 
screening of individuals over 50 years of age can be expected to identify 
PAD in nearly one-third of individuals. Furthermore, identifying PAD 
before it has progressed to its more severe stages in this population allows 
us to offer effective treatments. These therapies may arrest PAD 
development and perhaps, as we have seen with regression of 
atherosclerosis through aggressive blood pressure and lipid control, 
reverse its advance. At the same time, we will undoubtedly be reducing 
cardiovascular risk. 
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MATERIALS AND METHODS 
MATERIALS 
The present study was a cross sectional study carried out between 
May and November 2011 on patients who were admitted to the Rajiv 
Gandhi Government General Hospital, Chennai, a tertiary care referral 
hospital in Tamilnadu. The protocol of the study was approved by the 
Institutional Ethics Committee, Madras Medical College, Chennai- 
600003 and detailed informed written consent was obtained prior to 
enrolment in the study from the patient. 
STUDY POPULATION 
One hundred (100) patients admitted to the various medical wards 
and attending the outpatient clinics of Rajiv Gandhi Government General 
Hospital, Chennai were enrolled for the present study. 
INCLUSION CRITERIA 
Patients with type 2 DM  without established cardiovascular 
symptoms and disease (as per the records available with them) 
EXCLUSION CRITERIA 
• Patients with type 2 DM with previous history of established 
cardiovascular disease.(as per the records available with them) 
• Patients with type 2 DM with cardiac symptoms (angina and 
angina equivalents) 
• All type 1 DM patients 
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• Patients with established/clinically manifested calcification of 
peripheral arteries 
• Patients with vasculitis 
• Patients with type 2 DM with established PAD in the form of 
gangrene and amputation in legs. 
 
METHODS 
 
¾ Each patient was interviewed to obtain detailed history and  
examined thoroughly including all peripheral pulses and bruit. 
¾ Height, weight and waist circumferences were measured with  
standardized techniques and equipments in all patients. Waist 
Circumference measured at midpoint between the costal margin 
and anterior superior iliac spine. Hip Measurement taken as 
maximum diameter at the greater trochanter. 
¾ BMI and Waist hip ratios were computed in all patients.   
BMI calculated based on the Quetelet formula by dividing weight 
(in kg) by the square of height (in m2).  
BMI was taken as <18.5 - underweight, 18.5-22.9 - normal, 23-
24.9 - overweight, >25 - obese.  
WHR - > 0.85 – was taken as abnormal value in female. > 0.90 in 
male as abnormal value. 
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¾ Blood pressure was measured in sitting position in the right upper 
limb in all patients.  Patients were considered as hypertensive if 
blood pressure was > 130/80 mm Hg or patients already on 
antihypertensive therapy. 
¾ Serum total cholesterol, triglycerides, HDL, LDL estimation were 
done after 12 hours of fasting in all patients. 
Dyslipidemia was taken as total cholesterol >200mg/dl or 
triglycerides >150mg/dl or LDL >130mg/dl or HDL <40 (males), < 
50 (females) 
¾ Fasting and post prandial blood sugar, HbA1c, serum creatinine 
were done in all patients.  
Fasting blood sugar measured after 8 hours of overnight fasting 
and post prandial blood sugar measured 2 hours after the meals. 
Fasting Hyperglycemia means if Blood glucose value ≥126 mg/dl 
and Post prandial hyperglycemia means if value ≥200 mg/dl. 
HbA1c <7 was taken as under good glycemic control and HbA1c 
≥7 was taken as not in good glycemic control. 
¾ ECG and Echocardiographic evaluation were done to rule out the 
presence of previous heart disease. 
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TREADMILL TEST 
Treadmill test was done for all patients in Department of 
Cardiology following the BRUCE protocol under the supervision of a 
well experienced cardiologist. 
Patient Preparation 
• Patients were instructed not to eat or smoke for 3 hours before the 
test and should be dressed appropriately for exercise, especially 
with regard to footwear. No unusual physical efforts should be 
performed for at least 12 hours before testing. 
• Drugs such as ß blockers or nitrates were withdrawn 24 hours prior 
to testing as it may attenuate the exercise responses and limit the 
test interpretation. 
• A brief history and physical examination were done to rule out any 
contraindications.  
• A resting standard 12-lead electrocardiogram (ECG) was obtained 
to rule out any differences from the resting pre-exercise ECG. 
• Standing ECG and blood pressure were recorded to determine 
vasoregulatory abnormalities and positional changes, especially 
ST-segment depression. 
• A detailed explanation of the testing procedure was given to the 
patient which outlines risks and possible complications. The 
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patients were instructed on how to perform the test with 
demonstration by the investigator. 
BRUCE PROTOCOL104 
The Bruce protocol is very widely used and has been extensively 
validated. There are 7 stages of 3 minutes each so that a complete test 
takes 21 minutes. First stage starts at a speed of 1.7 miles per hour (mph) 
and a gradient of 10%. Each subsequent stage has an increment of 0.7 to 
0.8 mph in speed and 2% in gradient. The level of exercise is estimated in 
METs where 1 MET (metabolic equivalent) is the amount of energy 
expended at rest or 3.5 ml oxygen per kilogram per minute.This can be 
better explained with the help of the following table. 
Bruce Protocol  
Stage Minutes % grade km/h MPH METS 
1 3 10 2.7 1.7 4.7 
2 6 12 4.0 2.5 7.0 
3 9 14 5.4 3.4 10.1 
4 12 16 6.7 4.2 12.9 
5 15 18 8.0 5.0 15.0 
6 18 20 8.8 5.5 16.9 
7 21 22 9.6 6.0 19.1 
MPH - miles per hour, METS – metabolic equivalents 
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An adequate test is performed if the patient can achieve 85% of 
their maximum heart rate (calculated as 220-age in years for men and 
210-age for women). 
The modified Bruce protocol has two 3-minute warm up stages at 1.7 
mph and 0% grade and 1.7 mph and 5% grade, and it is used in older 
individuals and those whose exercise capacity is limited (post MI) 
Exercise Test Supervision 
Exercise testing was conducted by well trained personnel with a 
sufficient knowledge of exercise physiology and equipments, 
medications, and personnel trained to provide advanced cardiopulmonary 
resuscitation (CPR) was readily available. 
Exercise Test Interpretation 
Interpretation of the test was done by well experienced cardiologist 
in department of Cardiology by taking exercise capacity and clinical, 
hemodynamic, and ECG responses into consideration. Exercise testing 
was terminated by following the indications given by ACC/AHA104. 
Indications for Terminating Exercise Testing: 
Absolute Indications 
• ST-segment elevation (>1.0 mm) in leads without Q waves (other 
than V1 or aVR). 
• Drop in systolic blood pressure >10 mm Hg (persistently below 
baseline), despite an increase in workload, when accompanied by 
any other evidence of ischemia. 
• Moderate-to-severe angina (grade 3 to 4) 
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• Central nervous system symptoms (eg. ataxia, dizziness, or near 
syncope). 
• Signs of poor perfusion (cyanosis or pallor). 
• Sustained ventricular tachycardia. 
• Technical difficulties monitoring the ECG or systolic blood 
pressure. 
• Subject’s request to stop. 
 
Relative Indications 
• ST or QRS changes such as excessive ST displacement (horizontal 
or down-sloping of >2 mm) or marked axis shift. 
• Drop in systolic blood pressure >10 mm Hg (persistently below 
baseline) despite an increase in workload, in the absence of other 
evidence of ischemia. 
• Increasing chest pain. 
• Fatigue, shortness of breath, wheezing, leg cramps, or claudication. 
• Arrhythmias other than sustained ventricular tachycardia, including 
multifocal ectopic, ventricular triplets, supraventricular 
tachycardia, heart block, or bradyarrhythmias. 
• General appearance. 
• Hypertensive response (systolic blood pressure >250 mm Hg 
and/or diastolic blood pressure >115 mm Hg). 
• Development of bundle-branch block that cannot be distinguished 
from ventricular tachycardia. 
 
ANKLE BRACHIAL INDEX 
All ABI were measured in a temperature controlled room (24° ± 1 
°C) where each subject rested supine for 5 minutes before measurements 
were started. ABI was measured by an examiner with experience in ABI 
measurement and who was blinded to all clinical baseline parameters. 
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Doppler assisted ABI measurements were performed  according to 
the method described by Lovelace and Moneta105 using a 
sphygmomanometer  with a cuff width ranging between 29 and 40 cm 
and a Doppler device with an 8.2 MHz continuous wave probe.  
An appropriate sized blood pressure cuff was placed on the arm 
with the limb at the level of the heart. Ultrasound gel was placed over the 
patient’s brachial pulse. Transducer of the handheld Doppler was placed 
on the gel and the position of the transducer was adjusted till the 
maximum intensity of the signal was obtained. The cuff was inflated to 
about 20mmHg above the expected systolic BP of the patient till the 
doppler signal was disappeared. Then the cuff was slowly deflated 
approximately 1mmHg/sec until the Doppler signal re-appears. This was 
taken as the brachial systolic pressure. Similarly brachial systolic BP was 
measured in other upper limb.  
In lower limbs, an appropriate sized blood pressure cuff was 
applied immediately proximal to the medial  malleoli. The ultrasound gel 
was placed on the skin overlying the dorsalis pedis (DP) and posterior 
tibial (PT) arteries in the foot. Transducer of the handheld Doppler was 
placed on the gel and the position of the transducer was adjusted till the 
maximum intensity of the signal was obtained. Then the cuff was slowly 
inflated till no longer the signal was heard. Then the cuff was deflated 
using the same technique used in the arms until the Doppler signal re-
37 
 
appears. This measurement was taken as systolic BP in DP of that limb. 
Similarly the systolic pressure of the PT was obtained. The same was 
repeated on the opposite leg. 
Calculated ABI values were adjusted to 2 decimal places. 
The diagnostic criteria for PAD106 based on the ABI are interpreted as 
follows: 
• Normal if 0.91–1.30 
• Mild obstruction if 0.70–0.90 
• Moderate obstruction if 0.40–0.69 
• Severe obstruction if  < 0.40 
• Poorly compressible if  > 1.30 
 
STATISTICAL ANALYSIS 
The data collected from the patients were entered in to the master 
chart prepared. The statistical analysis was done using GRAPH PAD 
PRISM version 5.0. For non-parametric data, Fisher’s exact test was 
used. For parametric data, student’s t-test or ANOVA (ANalysis of One 
way VAriance) was done as deemed appropriate to the data of interest. 
The significance of the statistical test was graded as * – significant (p < 
0.05), ** – very significant (p<0.01), *** – highly significant (p<0.001), 
**** – very highly significant (p<0.0001), # – not significant. 
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OBSERVATIONS AND ANALYSIS 
AGE DISTRIBUTION 
Age of the 100 patients selected for the study ranges from 37 to 60 years. 
 
TABLE 1: AGE DISTRIBUTION 
AGE OF PATIENT NO. OF PATIENTS 
31-40 9 
41-50 40 
51-60 51 
 
 
GENDER DISTRIBUTION 
Gender distribution of the 100 patients selected randomly for the study 56 
were males and the remaining 44 were females. 
 
TABLE 2 : GENDER DISTRIBUTION 
SEX NO. OF PATIENTS 
MALE 56 
FEMALE 44 
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SHT 
Among the 100 patients studies 43 had hypertension. Majority of the 
hypertensive were males 26(60.47%). Largest number of hypertensive 25 
(58.14%) were in the 50-60 years age group. 
TABLE 3 : SHT AND SMI 
 
NO SMI YES SMI 
NO % NO % 
NORMOTENSIVES 51 61.45 6 35.29 
HYPERTENSIVES 32 38.55 11 64.11 
TOTAL 83  17  
P VALUE 0.0613#
 
There was no statistically significant correlation between hypertension 
and SMI. 
ACTIVE SMOKER 
None of the females were active smokers. Out of the 56 males 34 
(60.71%) were active smokers.                                                                                         
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TABLE 4:  SMOKING AND SMI 
 NO SMI YES SMI 
NO % NO % 
NONSMOKER 56 67.47 10 58.82 
SMOKER 27 32.53 7 41.18 
TOTAL 83  17  
P VALUE  0.5768#  
 
No significant correlation between smoking and SMI. 
ALCOHOLIC 
Among the 100 patients studied only male alcoholics were found. Out of 
the 56 males 35 (62.5%) were alcoholics.                                                                     
TABLE 5: ALCOHOL AND SMI 
 
NO SMI SMI 
NO % NO % 
NON ALCOHOLIC 53 63.86 12 70.59 
ALCOHOLIC 30 36.15 5 29.41 
TOTAL 83  17  
P VALUE 0.7815#  
 
No significant correlation between alcohol and SMI. 
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BMI 
AGE AND BMI 
Among the 100 patients studied 49 of them belongs to overweight and 
obese category and 51 of them belongs to normal and underweight 
category. 
As age increases there is no significant increase in BMI and majority 
31(60.78%) of the 51-60 years age group were normal and underweight. 
                                         
TABLE 6: AGE AND BMI 
 
No statistically significant correlation between age and BMI. 
 
 
 
 
AGE 
GROUP 
                                               BMI 
UNDER 
WEIGHT 
NORMAL 
OVER 
WEIGHT 
OBESE 
NO % NO % NO % NO % 
31-40 0 0 2 5 4 14.29 3 14.29 
41-50 4 36.36 14 35 14 50 8 38.09 
51-60 7 63.67 24 60 10 35.71 10 47.62 
TOTAL 11 100 40 100 28 100 21 100 
MEAN         17.14         21.07          24.03         28.69 
S.D.          1.04         1.37            0.56          5.25 
P VALUE                                                  1 #
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SEX AND BMI 
Among the 56 males in my study 30(53.57%) belongs to normal 
and underweight category and the remaining 26 (46.43%) belongs to 
overweight and obese category. 
Among the 44 females i have studied 23 (52.27%) belongs to 
overweight and obese category and the remaining 21 (47.73%) belongs to 
normal and underweight category. 
There was a slight increase in BMI  among females compared to 
males but this difference was not significant statistically. 
 
TABLE 7 : SEX AND BMI 
 
SEX 
BMI 
UNDER 
WEIGHT 
NORMAL OVER 
WEIGHT 
OBESE 
NO % NO % NO % NO % 
MALES (56) 10 17.86 20 35.71 15 26.79 11 19.64 
FEMALES(44) 1 2.27 20 45.45 13 29.55 10 22.73 
P VALUE                                   0.6873#  
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TABLE 8: BMI ANS SMI 
BMI NO SMI YES SMI 
MEAN±S.D 22.56±0.3841 25.52±1.664 
P VALUE  <0.0100**  
 
There was a statistically significant correlation between BMI AND SMI. 
W/H RATIO 
SEX AND W/H RATIO 
Among the 44 females 37 (84.09%) were having high W/H ratio 
and only 36 (64.29%) out of the 56 males were having high W/H ratio. 
Females having high W/H ratio compared to males. 
 
TABLE 9 : SEX AND W/H RATIO 
 
SEX 
WAIST HIP RATIO 
NORMAL HIGH 
NO % NO % 
MALES (56) 20 35.71 36 64.29 
FEMALES (44) 7 15.91 37 84.09 
P VALUE 0.0402*
 
There is a stasitically significant relationship between sex and BMI. 
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WAIST CIRCUMFERENCE 
SEX AND WAIST CIRCUMFERENCE 
Among the 44 females 30 (68.18%) of them having high waist 
circumference and only 13 (23.21%) out of the 56 males having WC on 
the high side. Females having high waist circumference compared to 
males. 
TABLE 11: SEX AND WAIST CIRCUMFERENCE 
 
SEX 
WAIST CIRCUMFERANCE 
NORMAL HIGH 
NO % NO % 
MALES (56) 43 76.79 13 23.21 
FEMALES (44) 14 31.82 30 68.18 
P VALUE <0.0001****
 
There was a statistically significant correlation between sex and WC. 
TABLE 12: WC AND SMI 
WC NO SMI YES SMI 
MEAN±S.D. 83.46±8.09 88.59±12.65 
P VALUE  0.0346*
 
There was a statistically significant positive correlation WC and SMI. 
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TABLE 13: SEX AND HbA1c 
 
SEX 
HbA1c 
<7 ≥7 
NO % NO % 
MALES (56) 12 21.43 44 78.57 
FEMALES (44) 11 25 33 75 
TOTAL (100) 23  77  
P VALUE  0.8114#  
 
HbA1c AND DURATION OF DIABETES 
Out of the 47 patients who had diabetes for more than 5 years 43(91.49%) 
patients have HbA1c ≥7 compared to 53 of the diabetics of less than 5 
years only  34 (64.15%) of them have HbA1c ≥7. 
As duration of diabetes increases many of the patients have not in good 
control of blood sugar and it was statistically significant. 
 
TABLE 14 : DURATION OF DM AND HbA1c 
 
DURATION OF DM 
(YEARS) 
HbA1c 
<7 ≥7 
NO % NO % 
≤5 19 35.85 34 64.15 
>5 4 8.51 43 91.49 
TOTAL 23  77  
P VALUE 0.0016**  
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DYSLIPIDEMIA: 
SEX AND DYSLIPIDEMIA 
Among the 100 patients studied 55 of them having dyslipidemia. 
50% dyslipidemic in males and 61.36% dyslipidemic among females. 
Females have more dyslipidemia compared to males but the difference 
was not statistically significant. 
 
TABLE 16 : SEX AND DYSLIPIDEMIA 
LIPIDS 
MALES FEMALES 
NO % NO % 
NORMAL 28 50 17 38.64 
DYSLIPIDEMIA 28 50 27 61.36 
TOTAL 56  54  
P VALUE 0.3130# 
 
DURATION OF DM AND DYSLIPIDEMIA 
Among the 47 patients in DM of more than 5 years category 38 
(80.85%) of them having dyslipidemia compared to only 17 (32.08%) out 
of 53 of them in the DM less than and equal to 5 years category. 
Dyslipidemia was more common in DM of more than five years duration. 
This difference was statistically significant. 
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TABLE 18: DYSLIPIDEMIA AND SMI 
 NO SMI YES SMI 
DYSLIPIDEMIA 40 (48.19%) 15 (88.24%) 
P VALUE 0.0027**
 
SMI was more common in DM patients with dyslipidemia. 
There was a statistically significant positive correlation between 
dyslipidemia and SMI. 
ABI 
Among the 100 patients studied only 14 of them having low ABI (≤0.9). 
81 of them belongs to normal ABI (0.91-1.3) category and the remaining 
5 of them belongs to high ABI (>1.3) category. 
There was not much significant difference between males and females. 
 
TABLE 19: SEX AND ABI 
ABI 
MALES FEMALES 
NO % NO % 
≤0.9 8 57.14 6 42.86 
0.91-1.3 46 56.79 35 43.21 
>1.3 2 40 3 60 
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TABLE 20: ABI AND DURATION OF DM 
DURATION OF 
DM(YEARS) 
ABI 
≤0.9 >0.9 
≤5 0 53 
>5 14 33 
P VALUE  <0.0001****  
 
As duration of DM increases ABI value decreases and there was 
statistically significant correlation between them. 
ABI AND HbA1c 
Among the 14 patients having ABI ≤0.9, all the 14 (100%) belongs to 
HbA1c ≥7 category  and out of the 86 patients having ABI >0.9 only 63 
(73.26%) belongs to HbA1c ≥7 category. 
There was a significant correlation between ABI and HbA1c. 
TABLE 21: ABI AND HbA1c 
 
HBA1c 
ABI 
≤0.9 >0.9 
NO % NO % 
<7 0 0 23 26.74 
≥7 14 100 63 73.26 
TOTAL 14  86  
P VALUE 0.0354*  
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TMT  
Among the 100 patients studies 17 have positive TMT AND 83 have 
negative TMT. 
TABLE 22 : TMT 
TMT NO. OF PATIENTS PERCENTAGE (%) 
           POSITIVE                  17                    17 
           NEGATIVE                  83                    83 
 
SEX AND TMT 
Among the 17 patients having positive TMT 10 (58.82%) were males and 
7 (41.18%) were females. 
Although it appears as males have more TMT positivity this difference 
was not statistically significant. 
TABLE 23 : SEX AND TMT 
 
TMT 
MALES FEMALES 
NO % NO % 
POSITIVE 10 58.82 7 41.18 
NEGATIVE 46 55.42 37 44.58 
P VALUE  1.000#
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TMT AND DURATION OF DM 
All of the 17(100%) patients having POSITIVE TMT belong to DM of 
>5 years duration and only 30 (36.14%) out of the 83 TMT NEGATIVE 
patients belongs to DM of >5 years. 
As the duration of the diabetes increases the TMT positivity also increase 
and this was highly significant statistically. 
 
TABLE 24: TMT AND DURATION OF DM 
 
DURATION OF DM 
(YEARS) 
TMT 
POSITIVE NEGATIVE 
NO % NO % 
≤5 0 0 53 63.86 
>5 17 100 30 36.14 
TOTAL 17  83  
P VALUE  <0.0001****  
 
TABLE 25: DURATION OF DM AND SMI 
DURATION OF DM 
(years) 
NO SMI SMI 
MEAN±S.D. 5.13±3.38 11.41±3.45 
P VALUE  <0.0001****
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TABLE 26: ABI AND TMT 
 
ABI 
TMT 
POSITIVE NEGATIVE 
NO % NO % 
≤0.9 14 87.50 0 0 
0.91-1.3 2 12.50 79 100 
TOTAL 16  79  
P VALUE  <0.0001****  
 
TABLE 27: ABI AND TMT 
ABI 
TMT 
POSITIVE NEGATIVE 
NO. % NO. % 
0.91-1.3 2 66.67 79 95.18 
>1.3 1 33.33 4 4.82 
TOTAL 3  83  
P VALUE 0.1663#
 
 
TABLE 28: ABI AND SMI 
ABI NO SMI YES SMI 
MEAN±S.D. 1.14±0.09 0.87±0.19 
P VALUE  <0.0001****  
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BASELINE CHARACTERISTICS OF THE STUDY POPULATION 
 
 
PARAMETER 
 
NO SMI 
 
YES SMI 
 
P VALUE 
No. of Patients 83 17  
Age (years) 49.87±6.22 54.24±3.11 0.0059**
DM Duration(Years) 5.13±3.38 11.41±3.45 <0.0001****
BMI 22.56±3.5 22.56±3.5 <0.0100***
W/H RATIO 0.8917±0.07 0.8882±0.01 0.8465#
WC 83.46±8.09 88.59±12.65 0.0346*
Dyslipidemia(n(%)) 40(48.19%) 15(88.24%) 0.0027**
Hypertension(n(%)) 32(38.55%) 11(64.71%) 0.0613#
Smoking(n(%)) 27(32.53%) 7(41.18%) 0.5768#
Alcoholism(n(%)) 30(36.14%) 5(29.41%) 0.7815#
HbA1c 7.57±1.1031 8.51±1.1459 0.0021**
ABI 1.14±0.09 0.87±0.2 <0.0001****
 
* – SIGNIFICANT (p < 0.05), ** – VERY SIGNIFICANT (p<0.01), *** – HIGHLY SIGNIFICANT 
(p<0.001), **** – VERY HIGHLY SIGNIFICANT (p<0.0001), # – NOT SIGNIFICANT 
Results are reported as Mean ± Standard deviation and as mean with range 
wherever applicable. Difference between means for parametric data was calculated 
using the student’s unpaired t-test with two tailed p value. Difference between means 
for non-parametric data was calculated using Mann-Whitney test with two tailed p 
value. Difference between proportions was calculated using Fisher’s exact test with 
two tailed p value. 
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DISCUSSION 
AGE 
In our study of 100 patients majority of them (91%) of them 
belongs to 41-50 years age group. In our study we found that the average 
age for patients with SMI was 54.24±3.11 and without SMI was 
49.87±6.22. As age increases chance of getting SMI also increases in type 
DM patients and there was stastistically significant correlation between 
the two with P value  of 0.0059. 
In DIAD STUDY107 they found that the age for the patients with 
SMI ranges from 61- 64years . Compared to that study the average age at 
which SMI was diagnosed was lower in our study. In another study 
conducted in Turkish population by Ugur-Altun B et al108 they found that 
the average age in SMI group was 55±3 which was almost nearer to our 
study. In another study conducted by Kim MK et al109 the average age 
group in patients with SMI was 63.1±9.4 and compared to this study the 
age group was lower in our study. 
GENDER 
In our study of 100 patients 56 were males and 44 were females. 
Among the 17 patients having positive TMT 10 (58.82%) were males and 
7 (41.18%) were females. Although it appears as males have more TMT 
positivity this difference was not statistically significant. 
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In DIAD STUDY107 they found that men have more SMI in the 
form of large perfusion abnormality than women.Ugur-Altun B et al108 
found in their study that no sex preference in patients with SMI. The 
prevalence of SMI was almost similar in both males and females in a 
study done by AK Agarwal et al110 in New Delhi. 
HYPERTENSION 
Among the 100 patients studied 43 had hypertension. Majority of 
the hypertensive were males 26(60.47%). Largest number of hypertensive 
25(58.14%) were in the 51-60 age group. Among the 17 SMI patients 11 
were having hypertension. Even though it appears as SMI was common 
in patients with associated SHT there was no statistically significant 
correlation between them with a P value of 0.0613. 
In a study done by Lubaszewski W et al111 they found that SMI was 
more frequent in patients with type 2 DM and essential hypertension. 
ACTIVE SMOKING 
Out of the 56 males 34 (60.71%) were active smokers. None of the 
females were active smokers. Of the 17 patients having SMI only 7 of 
them were active smokers and there was no statistically significant 
correlation between smoking and SMI with a P value of   0.5768. The 
cardiovascular burden of diabetes increases in combination with smoking. 
In DIAD study107 they found that active smoking have no 
significant impact on SMI. In a study by AK Agarwal et al110 the 
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prevalence of smoking in SMI is 9.1% and no correlation with SMI 
statistically. 
ALCOHOLISM 
Among the 100 patients studied only male alcoholics were found. 
Out of the 56 males 35 (62.5%) were alcoholics. In our study out of the 
17 SMI patients only 5 were alcoholic and 12 were non alcoholic and 
there was no significant correlation between the two with a P value of 
0.7815. 
In DIAD study107 they found that alcoholism has no significant 
impact on SMI. In AK Agarwal et al110 study the prevalence of heavy 
alcohol consumption was 9.1%. and there were more alcoholics in the 
NON SMI group similar to in our study. 
BODY MASS INDEX 
Among the 100 patients studied 49 of them belongs to overweight 
and obese category and 51 of them belongs to normal and underweight 
category. As age increases there was no significant increase in BMI and 
majority 31(60.78%) of the 51-60 years age group were normal and 
underweight. There was no statistically significant relation between age 
and BMI with a P value of 1. Among the 56 males in my study 
30(53.57%) belongs to normal and underweight category and the 
remaining 26 (46.43%) belongs to overweight and obese category. 
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Among the 44 females i have studied 23 (52.27%) of them belongs to 
overweight and obese category and the remaining 21 (47.73%) of them 
belongs to normal and underweight category. There was a slight increase 
in BMI  among females compared to males and this was not signifiant 
statistically with a P value of 0.6873. The mean BMI in patients with SMI 
was 25.52±1.664 and that of the NON SMI group was 22.56±0.3841 and 
this difference was statistically significant with a P value of 0.01. 
In DIAD study107 the average BMI in patients with SMI ranges 
from 30-32.5 and in our study it was on the lower side. In AK Agarwal et 
al110 study in SMI group 54.54% were obese and in NON SMI group 
59.26% were obese and this difference not significant statistically. In a 
study by Gomez Martinez et al112 they found that the average BMI in SMI 
and NON SMI groups were 30.6±3.8 and 30.4±4.2 and no significant 
difference between them. 
WAIST HIP RATIO 
In our study among the 44 females 37 (84.09%) were having high 
W/H ratio and only 36 (64.29%) out of the 56 males were having high 
W/H ratio. Females having high W/H ratio compared to males.There was 
stasitically significant relationship between sex and BMI.In our study the 
average W/H ratio in patients with SMI was 0.8882±0.01 and in NO SMI 
group it was 0.8917±0.07 and there was no statistical significant 
correlation between W/H ratio and SMI. 
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In Gomez Martinez et al112  study they found that the average W/H ratio 
SMI group was 1.02±0.05 and in NON SMI group it was 1.00±0.06 and 
no significant relation between them. In AK Agarwal et al110 study the 
average W/H ratio in SMI and NON SMI groups were 0.91±0.09 and 
0.92±0.01 and not significant statistically. 
WAIST CIRCUMFERENCE 
In our study among the 44 females 30 (68.18%) of them having high 
waist circumference and only 13 (23.21%) out of the 56 males having 
WC on the high side. Females having high waist circumference compared 
to males. There was statistically significant correlation between sex and 
WC with a P value of <0.0001. In our study the average WC in patients 
with SMI was 88.59±12.65 and in NON SMI group it was 83.46±8.09 
and there was significant positive correlation between WC and SMI with 
a P value of 0.0346. 
HbA1c 
Among the 56 males 44(78.57%) of them have HbA1c ≥7 and 33 
(75%) out of the 44 females were having HbA1c ≥ 7.Eventhough it 
appears as males having poor control of blood sugar than males the 
difference was not statistically significant with a P value of 0.8114. 
In AK Agarwal et al110 study the average HbA1c LEVEL in males 
and females were 7.17±1.77 and 7.38±1.18 and not much difference in 
among them. Out of the 47 patients who had diabetes for more than 5 
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years 43(91.49%) patients have HbA1c ≥7 compared to 53 of the 
diabetics of less than 5 years only  34 (64.15%) of them have HbA1c ≥7. 
As duration of diabetes increases many of the patients have not in good 
control of blood sugar and it was statistically significant. In our study the 
average HbA1c level in patients with SMI is 8.51±1.1459 and in NON 
SMI group was 7.57±1.1031. SMI is common in patients with poorly 
controlled diabetes and this difference was statistically significant with a 
P value of 0.0021. In a study done by AK Agarwal et110 they found that 
the average HbA1c level in patient with SMI and NON SMI groups were 
7.68±1.40 and 7.71±1.71, not much significant difference between them. 
DURATION OF DIABETES 
All of the 17(100%) patients having SMI belong to DM of >5 years 
duration and only 30 (36.14%) out of the 83 NON SMI patients belongs 
to DM of >5 years. In our study the mean duration of  DM in SMI group 
was 11.41±3.45 and that of NON SMI group was 5.13±3.38 and there 
was statistically significant difference between them. As the duration of 
the diabetes increases the SMI also increase and this was highly 
significant statistically with a P value of <0.0001. 
In a study done by Kim MK et al109 they found that the positive 
predictive value of treadmill test increased to 87.5%  in elderly patients 
≥60 years with long duration of DM ≥10 years. In a study done by AK 
Agarwal et al110 they found that the average duration of DM in patients 
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with SMI was 11.19±7.06 and that of  NON SMI group it was 9.70±5.92 
and there was no statistical difference between them. 
DYSLIPIDEMIA 
Among the 100 patients studied 55 of them having dyslipidemia. 
50% dyslipidemic in males and 61.36% dyslipidemic among females. 
Females have more dyslipidemia compared to males but the difference 
was not statistically significant with a P value of 0.3130.Among the 47 
patients in DM of more than 5 years category 38 (80.85%) of them 
having dyslipidemia compared to only 17 (32.08%) out of 53 of them in 
the DM less than and equal to 5 years category. Dyslipidemia was more 
common in DM of more than five years duration. This difference was 
statistically significant with a P value of  < 0.0001. In our study 88.24% 
of patients have dyslipidemia in the SMI group and only 48.19% have 
dyslipidemia in the NON SMI group and there was statistically 
significant correlation between the two with a P value of 0.0027. 
Dyslipidemia was more common in patients with SMI. 
In a study done by Gomez martinez et al112 they found that 
dyslipidemia was more common in NON SMI group but it was not 
significant statistically. 
ANKLE BRACHIAL INDEX 
Among the 100 patients studied only 14 of them having low ABI 
(≤ 0.9). 
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81 of them belongs to normal ABI (0.91-1.3) category and the remaining 
5 of them belongs to high ABI (>1.3) category. There was not much 
significant difference between males and females.In BARI 2D TRIAL113 
they found that females having low ABI compared to males. 
 In our study of 100 patients  all 14 patients having low ABI 
(≤0.9and all the 5 patients having high ABI ) belongs to DM >5years 
duration category. All of the remaining 53 patients having normal ABI 
have DM ≤5years duaration. As duration of DM increases ABI value 
decreases and there was statistically significant correlation between them 
with a P value of <0.0001. In BARI 2D TRIAL they stuidied that as 
duration of DM increases ABI value decreases. 
Among the 14 patients having ABI ≤0.9, all the 14 (100%) belongs 
to HbA1c ≥7 category  and out of the 86 patients having ABI >0.9 only 
63 (73.26%) belongs to HbA1c ≥7 category. There was significant 
correlation between ABI and HbA1c with a P value of 0.0354. In BARI 
2D TRIAL they found that no significant impact of HbA1c on ABI. 
TMT 
Among the 100 patients studies 17 have positive TMT AND 83 have 
negative TMT. Among the 17 TMT POSITIVE patients 14 (82.35%) of 
them have ABI ≤0.9 and among the 83 TMT NEGATIVE patients all of 
the have ABI >0.9. In our study we found that the average value of ABI 
in patients having  SMI and NO SMI were 0.87±0.2 and 1.14±0.09 
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respectively. As ABI decreases ≤0.9 the TMT POSITIVITY RATE 
increases and this was highly significant statistically with a P value of 
<0.0001. There was no statistically significant difference between the 
normal ABI (0.91-1.3) group and the high ABI (>1.3) group in terms of 
TMT POSITIVITY with a P value of 0.1663. 
In a study done by Gomez Martinez et al they found that the 
average value of ABI in patients having SMI was 0.91±0.21 and in NO 
SMI group it is 1.04±0.13 and it was significant statistically. 
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CONCLUSIONS 
The conclusions from this study are 
1. There was a significant association between low ABI and SMI 
2. The prevalence of SMI in our study was 17% as found in most 
studies. 
3. As age increases chance of getting SMI increases in asymptomatic 
type 2 DM and it was significant statistically. 
4. There was no gender preference in SMI in asymptomatic type 2 
diabetics. 
5. Traditional cardiac risk factors such as hypertension and smoking 
did not emerge as significantly predictive of abnormal tests. 
6. There was a significant association between HbA1c and low ABI 
in our study in contrast to many studies. 
7. Most of the asymptomatic type 2 diabetics having SMI were obese 
and there was a significant association between BMI, waist 
circumference and SMI. 
8. SMI was common in poorly controlled asymptomatic type 2 DM as 
there was a significant association between HbA1c and SMI. 
9. As duration of DM increases incidence of SMI also increases and 
there was a significant association between them. 
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10. Dyslipidemia emerged as one of the important predictor of SMI in 
asymptomatic type DM in our study and that association was 
statistically significant. 
 
This study was able to establish that a simple, cost effective and non-
invasive investigation like ABI can predict the presence of asymptomatic 
CAD in type 2 diabetics. This is more relevant in a developing country 
like India where the economic resources available with the common man 
preclude other invasive and costlier modalities of screening for 
asymptomatic patients. Even though the benefits of early detection of the 
asymptomatic disease and its treatment has not yet yielded a significant 
benefit to patients in the studies conducted so far, it remains to be decided 
only after long term studies with larger populations from the community 
like the DADDY-D trial113 come to a conclusion. Till then, in the diabetic 
capital of the world that is India, bearing in mind the simple and effective 
measures available for primary prevention, it is the only way forward as 
prevention is always better than the cure. 
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ANNEXURE 
 
“ANKLE BRACHIAL INDEX AS A PREDICTOR OF SILENT MYOCARDIAL 
ISCHEMIA IN ASYMPTOMATIC TYPE 2 DIABETES MELLITUS PATIENTS”          
- 
                                                              PROFORMA 
 
NAME :                                                                     ADDRESS : 
AGE/SEX : 
OCCUPATION :                                                        PHONE NO. 
 
COMPLAINTS 
Chest pain :                 Y/N 
Breathlessness :          Y/N 
Palpitation :                Y/N 
Swelling of legs :        Y/N 
Syncope :                    Y/N 
Claudication in legs    Y/N    
          
PAST HISTORY 
 
DM :                                               CAD: 
SHT :                                              STROKE/TIA: 
CKD :                                             CCF: 
 
Family H/O premature CAD : 
 
 
PERSONAL HISTORY  
Smoker : 
Alcoholic : 
GENERAL EXAMINATION 
BP :                                     PULSE : 
 
WEIGHT:                      HEIGHT :                       BMI :    
                                   
WAIST CIRCUMFERENCE:                                   WAIST/HIP :    
 
CAROTID BRUIT :                      RENAL BRUIT :                      FEMORAL BRUIT:  
INVESTIGATION   
BLOOD SUGAR : 
                  FASTING :                             POST PRANDIAL : 
HbA1C : 
S.CREATININE : 
FASTING LIPID PROFILE : 
       TOTAL CHOLESTEROL:                     TG:                      HDL:                   LDL: 
 
USG ABDOMEN : 
ECG IN ALL LEADS : 
ECHO : 
TREAD MILL TEST : 
ANKLE BRACHIAL INDEX(ABI) : 
   
S.No            NAME      AGE       SEX      DM(yrs)     SHT      CKD SMOKER ALCOHOLIC      BMI      WC      W/H    HbA1c DYSLIPIDEMIA      ABI      TMT
1 PATCHAPPAN 56 M 10        ‐         ‐        ‐          ‐ 20.06 81 0.95 8.3           + 0.72      +
2 GOPAL 54 M 3        ‐         ‐       +         + 22.67 87 0.95 6.9          + 1.16      ‐
3 MOHAN 43 M 6       +         ‐       ‐          ‐ 24.22 86 0.94 7.4           + 1.26       ‐
4 NAZEER 42 M 2        ‐         ‐       +          ‐ 23.14 92 0.98 7.1           ‐ 1.2       ‐
5 PERUMAL 58 M 5       +         ‐       ‐          ‐ 23.14 81 0.92 7.9          ‐ 1.21       ‐
6 DAKSHANAMOORTHY 56 M 15       +        +       +         + 24.11 80 0.97 10.6          + 0.86       +
7 RAMAKRISHNAN 56 M 10       ‐        ‐       +         + 16.54 79 0.89 8          + 1.13        ‐
8 KRISHNAN 53 M 8       ‐        ‐       +         + 17.31 78 0.88 7.4          + 1.23        ‐
9 SAGADEVAN 59 M 15       +       +       +         + 29.68 104 1.01 9.7          + 1.07        ‐
10 ANGAMUTHU 47 M 2       ‐        ‐       +         + 18.64 76 0.84 6.6          ‐ 1.19        ‐
11 MANI 50 M 10       ‐        ‐       +         ‐ 17.77 75 0.84 7.9          +  1.05        ‐
12 PALANI 57 M 14       ‐        ‐       +         + 22.49 89 0.95 7.9          + 0.68       +
13 MUNUSAMY RAJ 52 M 4       +        ‐       +         + 24.6 92 0.96 7          + 1.12       ‐
14 VASUDEVAN 40 M 3       ‐        ‐       +         + 19.2 87 1.1 6.5          + 1.11       ‐
15 MOHAN 50 M 10       +        ‐       ‐         ‐ 31.14 99 0.87 7.5          + 0.84       +
16 SUBRAMANIYAM 52 M 4       ‐        ‐       +         + 23.73 92 0.98 7          + 1.1        ‐
17 NAINA MOHAMMAD 52 M 5       ‐        ‐        ‐         ‐ 22.37 87 0.96 7.8          ‐ 1.14        ‐
18 DHAYALAN 42 M 2       ‐        ‐       +         + 22.03 86 0.93 6.7          + 1.17        ‐
19 JEYARAJ 46 M 4       ‐        ‐       +         + 23.98 96 0.98 10.1           ‐ 1.1        ‐
20 THANGARAJ 45 M 1        ‐        ‐       +         + 24.8 89 0.92 6.9           ‐ 1.26        ‐
21 SANGAIAH 55 M 3       +        ‐        ‐         ‐ 19.81 81 0.94 7.3           ‐ 1.08        ‐
22 EGAMBARAM 55 M 10       +        ‐       +         ‐ 22.6 85 0.95 8.8          + 0.98        ‐
23 NEELAKANDAN 45 M 1       +        ‐       +         +   17.7 90 0.97 6.7           ‐ 1.16        ‐
24 SRINIVASAN 39 M 3        ‐        ‐        ‐          ‐ 23.62 80 1.05 7.7           ‐ 1.16        ‐
25 MANIVANNAN 42 M 3        ‐        ‐       +         + 25.46 93 0.93 7.1           ‐ 1.19        ‐
26 MOHAN 49 M 5        ‐        ‐       +         + 22.37 87 0.96 7.5          + 1.1        ‐
27 JAYAKRISHNAN 59 M 7       +        ‐        ‐          ‐ 26.33 98 1 7.9          ‐ 1.15        +
28 VELAYUTHAM 47 M 5        ‐        ‐        ‐           ‐ 23.45 76 0.9 8.9          ‐ 1.21        ‐
29 ALBERT 47 M 3       +        ‐        ‐           ‐ 20.43 80 0.9 7          ‐ 1.09        ‐
30 KAMALNADHAN 60 M 3       +        ‐       +          + 25.01 90 0.88 9.5          ‐ 1.12        ‐
31 DURAISAMY 55 M 6       +        ‐       +           ‐ 18.36 71 0.85 8          + 1.03        ‐
32 NAGAPPAN 48 M 1        ‐        ‐        ‐          + 16.35 71 0.88 6.9           ‐ 1.24        ‐
33 MADHAVAN 53 M 15       +        ‐       +          + 25.21 87 0.91 11.5           + 0.69        +
34 GOPI 55 M 8        ‐        ‐       +          + 15.24 66 0.89 8.9           + 0.75        +
35 MUNUSAMY 54 M 10       +        ‐       +          + 20.76 87 0.95 8.7           + 0.96        ‐
36 RAVI 41 M 6       ‐        ‐        ‐          + 19.83 79 0.92 7.4            ‐ 1.11        ‐
37 SEKAR  46 M 6       +        ‐        ‐          + 25.71 91 0.91 7.7            ‐ 1.06        ‐
38 CHAND BASHA 49 M 11       +       +       +           ‐ 29.72 98 0.95 8.7           + 0.83       +
39 JAYASANKAR 37 M 4       +        ‐        ‐           ‐ 28.93 92 0.95 7.2           + 1.12        ‐
40 KESAVAMOORTHY 50 M 13       +        +         +          + 23.5 87 0.96 8.6           + 1.38        ‐
MASTER CHART
41 KRISHNAMOORTHY 55 M 3       +        ‐        ‐           ‐ 23.45 76 0.9 6.6           ‐ 1.14        ‐
42 RAJAPPA 43 M 4       +         ‐        +          + 24.14 92 0.98 7.1           ‐ 1.1        ‐
43 SAMBANATHAN 60 M 5       ‐        ‐        ‐          + 25.01 90 0.88 6.5           ‐ 1.12        ‐
44 SUBRAMANI 55 M 4       ‐         ‐        ‐          + 24.22 86 0.94 6.9            ‐ 1.18        ‐
45 SRIRAM 57 M 10        ‐         ‐        +          + 22.03 86 0.93 7.9           + 0.87       +
46 GOPAL 57 M 8       +         ‐        +          + 19.81 79 0.9 7.8           + 0.99        ‐
47 KRISHNAN 56 M 6       +         ‐         ‐          + 20.7 79 0.94 7.5            ‐ 1.07        ‐
48 RATHINAL 52 M 10       ‐         ‐         ‐          ‐ 20.43 80 0.9 9            + 1.03        ‐
49 MURUGESAN 45 M 3       ‐         ‐        +          + 23.45 76 0.9 6.7            ‐ 1.16        ‐
50 ARUL 45 M 5        ‐         ‐        ‐           + 18.36 77 0.9 7.6            ‐ 1.16        ‐
51 KRISHNARAJ 55 M 4       +         ‐        ‐          + 20.41 88 0.9 7.1            ‐ 1.1        ‐
52 SHANMUGAM 59 M 20       +        +       +          ‐ 17.15 74 0.85 9.7            + 1.4       +
53 BALU 54 M 6        ‐        ‐       +          + 25.46 93 0.93 7.9             ‐ 1.06        ‐
54 MOHAMMAD 55 M 7       +        ‐        ‐          ‐ 19.81 81 0.94 7            + 0.97        ‐
55 SHANKAR 53 M 5       ‐        ‐       +          + 18.67 75 0.86 7.8             ‐ 1.11        ‐
56 KOLLAPARI 60 M 2       ‐        ‐       +          ‐ 15.82 75 0.93 6.9             ‐ 1.24        ‐
57 MARY 46 F 12       ‐        ‐        ‐          ‐ 23.91 85 0.85 8.1              + 1.46        ‐
58 ABOORVAM 58 F 9       ‐        ‐        ‐          ‐ 21.33 85 0.86 8.9             + 1        ‐
59 SHANTHI 45 F 7       ‐        +        ‐           ‐ 19.02 66 0.81 9             + 1.02        ‐
60 PUSHPA 56 F 1        ‐        ‐        ‐           ‐ 17.98 65 0.77 7.5             + 1.19        ‐
61 MURUGAMMAL 55 F 15        +        ‐        ‐           ‐ 25.11 87 0.84 8.3             + 0.73        +
62 LALITHA 48 F 6         ‐        ‐        ‐           ‐ 27.08 101 1.08 13.8             + 1.12         ‐
63 KATTAMMAL 56 F 12        +        ‐         ‐           ‐ 22.5 74 0.93 7.9             + 1.06         ‐
64 SARASWATHY 48 F 3        +        ‐         ‐           ‐ 22.34 86 0.85 7.8             + 1.26         ‐
65 SHANTHI 43 F 6        ‐        ‐         ‐           ‐ 28.8 99 0.88 6.3             + 1.09         ‐
66 AMUDA 50 F 10       +        ‐         ‐           ‐ 35.55 100 0.82 7.5             + 0.88        +
67 INDHIRANI 53 F 1        ‐        ‐         ‐           ‐ 18.69 67 0.78 7             + 1.18        ‐
68 RANI 45 F 5        ‐        ‐        ‐           ‐ 18.73 68 0.78 7.9            + 1.11        ‐
69 KOUSALYA 50 F 4       +        ‐        ‐           ‐ 22.22 81 0.84 7.9            + 1.12        ‐
70 MUNIYAMMAL 55 F 3        ‐        ‐        ‐           ‐ 22.34 86 0.85 7.5            + 1.19        ‐
71 NIRANJANA 37 F 1       +        ‐        ‐          ‐ 27.88 99 0.88 6.8            + 1.2        ‐
72 SHAJATHI BEEVI 58 F 6       +         ‐        ‐          ‐ 24.77 92 0.85 6             ‐ 1.08        ‐
73 DAKCHAYINI 50 F 3       +         ‐        ‐          ‐ 21.08 74 0.83 7.4            + 1.12        ‐
74 SAKUNTHALA 50 F 3       +         ‐        ‐           ‐ 22.89 79 0.89 8            + 1.09        ‐
75 VENILA 53 F 13        ‐         ‐        ‐           ‐ 24.77 95 0.83 7.9            + 0.72        +
76 BHUVANESWARI 40 F 1        ‐         ‐         ‐           ‐ 39.87 100 0.82 7.2            + 1.16         ‐
77 SALAMMAL 55 F 6        ‐        +         ‐           ‐ 21.09 81 0.86 8.7           + 1.14         ‐
78 CHOKKAMMAL 50 F 5        ‐        ‐         ‐           ‐ 19.39 73 0.86 8            ‐ 1.09         ‐
79 VIMALA 49 F 7        ‐         ‐         ‐           ‐ 22.1 79 0.84 5.2            + 1.09         ‐
80 MUNNI 40 F 4       ‐        ‐         ‐           ‐ 23.3 81 0.85 6.5            ‐ 1.12         ‐
81 SARASU 57 F 5       ‐         ‐         ‐           ‐ 25.1 77 0.75 7.9            ‐ 1.06         ‐
82 ELAVARASI 39 F 4        ‐         ‐         ‐           ‐ 24.77 86 0.86 7.1            ‐ 1.18         ‐
83 MUTHAMMAL 55 F 7        ‐         ‐         ‐           ‐ 24.44 87 0.82 8.1            ‐ 1.12         ‐
84 MEERA 45 F 1        ‐         ‐        ‐           ‐  23.87 85 0.85 7.1            ‐ 1.18         ‐
85 NOORJAHAN 58 F 4        ‐         ‐        ‐           ‐ 22.5 81 0.82 7.6            ‐ 1.12         ‐
86 KASIYAMMAL 55 F 9       +        +        ‐           ‐ 22.1 79 0.84 9            + 0.85       +
87 DEVAGI 55 F 10       +         ‐         ‐           ‐ 44.44 121 0.86 7.4            + 1.2       +
88 MALLIKA 55 F 4       +         ‐         ‐           ‐ 22.22 79 0.87 7.7            ‐ 1.09        ‐
89 SAROJA 50 F 6       +         ‐         ‐           ‐ 25.96 84 0.77 6.9            ‐ 1        ‐
90 BALKESH 56 F 15       +        +         ‐           ‐ 21.08 75 0.76 8.1            + 1.42        ‐
91 PRIYA 50 F 10       +        ‐         ‐           ‐ 24.03 79 0.82 7.8            + 0.81       +
92 KRISHNAVENI 40 F 2       ‐         ‐         ‐           ‐ 22.6 88 0.88 6.9            ‐ 1.16        ‐
93 DEIVANI 50 F 2       +         ‐         ‐           ‐ 24.11 84 0.78 6.1            ‐ 1.12        ‐
94 KARPAGAVALLI 48 F 5       ‐         ‐         ‐           ‐ 24.77 93 0.84 7.7            ‐ 1.18        ‐
95 BADMAVATHY 50 F 8       ‐         ‐         ‐           ‐ 22.22 81 0.84 7.3           + 1.02        ‐
96 BAKIYALAKSHMI 55 F 15       ‐        ‐         ‐           ‐ 21.09 81 0.86 8.5            + 1.4        ‐
97 DHANABAKKIYAM 53 F 7       ‐         ‐         ‐           ‐ 24.44 87 0.82 7.8            ‐ 0.79       +
98 RADHA 38 F 1       ‐         ‐         ‐           ‐ 24.77 86 0.86 6.2            ‐ 1.2        ‐
99 MADHI 48 F 1       ‐         ‐         ‐          ‐ 23.3 81 0.85 6.7            ‐ 1.18        ‐
100 ADHILAKHSMI 57 F 3      +         ‐         ‐           ‐ 25.1 84 0.86 6.7            ‐ 1.12        ‐

